Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study)

Abstract

Purpose:

To evaluate the outcome of second-line intravitreal ranibizumab treatment in eyes with diabetic macular edema having persistent edema following initial therapy with intravitreal bevacizumab.

Methods:

Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel was a retrospective, multi-center study. Consecutive eyes with persistent diabetic macular edema following at least three previous intravitreal bevacizumab injections prior to intravitreal ranibizumab, at least three-monthly intravitreal ranibizumab injections and at least 12 months of follow-up were included. Data collected included demographics, ocular findings, diabetes control, details of intravitreal bevacizumab and ranibizumab injections, and visual and anatomical measurements before and after intravitreal ranibizumab treatment.

Results:

In total, 202 eyes of 162 patients treated at 11 medical centers across Israel were included. Patients received a mean (±standard deviation) of 8.8 ± 4.9 intravitreal bevacizumab injections prior to the switch to intravitreal ranibizumab. A mean of 7.0 ± 2.7 intravitreal ranibizumab injections were given during the 12 months following the switch to intravitreal ranibizumab. The median central subfield retinal thickness (±interquartile range) by spectral-domain optical coherence tomography decreased from 436 ± 162 µm at baseline to 319 ± 113 µm at month 12 (p < 0.001). Median logMAR visual acuity (±interquartile range) improved from 0.40 ± 0.48 at baseline to 0.38 ± 0.40 at month 12 (p = 0.001). Linear regression suggested that higher number of intravitreal ranibizumab injections and higher pre-switch central subfield retinal thickness were associated with favorable visual outcome. Higher number of intravitreal bevacizumab injections and the presence of intraretinal fluid before the switch lessened the odds of favorable outcome.

Conclusion:

Switching from bevacizumab to ranibizumab in persistent diabetic macular edema was associated with anatomical improvement in the majority of eyes and ⩾2 lines of vision improvement in 22% of eyes.

Keywords

Diabetic macular edema intravitreal anti-vascular endothelial growth factor bevacizumab ranibizumab

Get full access to this article

View all access options for this article.

References

Elman

Aiello

Beck

et al . Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064–1077.

Elman

Bressler

Qin

et al . Expended 2 year follow up of ranibizumab plus promt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609–614.

Brown

Nguyen

Marcus

et al . Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013–2022.

Michaelides

Kaines

Hamilton

et al . A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117: 1078–1086.

Rajendram

Fraser-Bell

Kaines

et al . A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012; 130: 972–979.

Wells

Glassman

Ayala

et al . Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016; 123: 1351–1359.

American Society of Retinal Specialists. Preferences and trends (PAT) survey. Chicago, IL: American Society of Retinal Specialists, 2016.

Katz

Moisseiev

Goldenberg

et al . Ranibizumab for persistent diabetic macular edema after bevacizumab treatment. Eur J Ophthalmol 2017; 27: 210–214.

Ehrlich

Dan

Deitch

et al . The effectiveness of intravitreal ranibizumab in patients with diabetic macular edema who have failed to respond to intravitreal bevacizumab. Ophthalmologica 2016; 235: 133–136.

10.

Hanhart

Chowers

Evaluation of the response to ranibizumab therapy following bevacizumab treatment failure in eyes with diabetic macular edema. Case Rep Ophthalmol 2015; 6: 44–50.

11.

Lee

Kim

SE.

Short-term outcomes of switching to ranibizumab therapy for diabetic macular edema in patients with persistent fluid after bevacizumab therapy. J Ocul Pharmacol Ther 2016; 32: 659–664.

12.

Ciulla

Hussain

Ciulla

et al . Ranibizumab for diabetic macular edema refractory to multiple prior treatments. Retina 2016; 36: 1292–1297.

13.

Dhoot

Pieramici

Nasir

et al . Residual edema evaluation with ranibizumab 0.5 mg and 2.0 mg formulations for diabetic macular edema (REEF study). Eye 2015; 29: 534–541.

14.

Ehlers

Spirn

Shah

et al . Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors. Ophthalmic Surg Lasers Imaging 2010; 41: 182–189.

15.

Kent

Iordanous

Mao

et al . Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration. Can J Ophthalmol 2012; 47: 159–164.

16.

Ferris

Maguire

Glassman

et al . Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema. JAMA Ophthalmol 2017; 135(2): 145–149.

17.

Gonzalez

Campbell

Holekamp

et al . Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol 2016; 172: 72–79.